| 83.52 -0.11 (-0.13%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 98.11 | 1-year : | 114.59 |
| Resists | First : | 84 | Second : | 98.11 |
| Pivot price | 83.77 |
|||
| Supports | First : | 53.78 |
Second : | 35.11 |
| MAs | MA(5) : | 83.74 |
MA(20) : | 81.64 |
| MA(100) : | 45.95 |
MA(250) : | 43.74 |
|
| MACD | MACD : | 8.9 |
Signal : | 10.3 |
| %K %D | K(14,3) : | 32.7 |
D(3) : | 54.1 |
| RSI | RSI(14): 90 |
|||
| 52-week | High : | 84 | Low : | 25.82 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CRNX ] has closed below the lower bollinger band by 4.2%. Bollinger Bands are 96.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 83.88 - 84.34 | 84.34 - 84.72 |
| Low: | 82.33 - 82.92 | 82.92 - 83.4 |
| Close: | 82.64 - 83.53 | 83.53 - 84.27 |
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Fri, 31 Jul 2026
Crinetics Pharmaceuticals (CRNX) holders to vote on $85-per-share cash sale to Vertex - Stock Titan
Thu, 30 Jul 2026
Crinetics Pharmaceuticals Inc (CRNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Thu, 30 Jul 2026
CRNX|Crinetics Pharmaceuticals Inc|Price:83.530|Chg%:-0.100 - TradingKey
Thu, 30 Jul 2026
Crinetics Pharmaceuticals Inc (CRNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tue, 28 Jul 2026
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: A Healthcare Innovator with Explosive Revenue Growth - DirectorsTalk Interviews
Fri, 24 Jul 2026
Crinetics Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRNX - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -242 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.0584e+008 (%) |
| Held by Institutions | 9.555e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.3911e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.14 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 307.7 % |
| Return on Equity (ttm) | -24.7 % |
| Qtrly Rev. Growth | 1.807e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -129.59 |
| EBITDA (p.s.) | -1.04981e+009 |
| Qtrly Earnings Growth | -5.4162e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -16.25 |
| Price to Sales | -0.65 |
| Price to Cash Flow | 0 |
| Dividend | 6.21e+006 |
| Forward Dividend | 1.286e+007 |
| Dividend Yield | 7435350% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|